Madagascar presents multiple disease risks absent or rare in most industrialized nations. Malaria transmission occurs year-round across the island below 1000 meters elevation, with Plasmodium falciparum accounting for approximately 90 percent of cases. The Central Highlands including Antananarivo experience lower transmission intensity than coastal areas, but the parasite remains present even at altitude. Chloroquine-resistant strains predominate throughout Madagascar. The CDC and WHO recommend prophylaxis for all travelers to endemic zones, with atovaquone-proguanil, doxycycline, and mefloquine representing the standard options. Coastal cities including Toamasina, Mahajanga, and Toliara maintain high transmission rates during the November-to-April rainy season. Anopheles mosquitoes breed in rice paddies throughout the Malagasy Coastal Plains and along river systems including the Mangoky and Betsiboka. Vector activity peaks between dusk and dawn. Insecticide-treated bed nets reduce exposure risk in accommodations without screening.
Plague represents an endemic health threat unique among popular travel destinations. Madagascar reports between 200 and 400 cases annually, making it the country with the highest contemporary incidence worldwide. Yersinia pestis circulates in rat populations throughout the Central Highlands, with human cases concentrated in Antananarivo and surrounding highland districts. Transmission occurs primarily September through April when temperatures support flea activity. Pneumonic plague outbreaks emerge sporadically in urban areas when cases progress from bubonic to respiratory transmission. A 2017 outbreak recorded 2348 confirmed and probable cases with 202 deaths between August and November. Antananarivo's dense informal settlements and Toamasina's port infrastructure represent the highest-risk environments. Prophylactic antibiotics exist but are not routinely prescribed for travelers. Risk remains low for visitors avoiding prolonged contact with rodent-infested structures, but the disease's presence distinguishes Madagascar from epidemiologically comparable destinations.
Schistosomiasis affects freshwater bodies throughout Madagascar. Both Schistosoma mansoni and Schistosoma haematobium infect human hosts through skin contact with contaminated water. The parasites complete their lifecycle in specific freshwater snail species present in slow-moving rivers, irrigation channels, and standing water across the Malagasy Coastal Plains. Lake Alaotra, Madagascar's largest lake, maintains known snail populations. Rice paddies surrounding Antsirabe and throughout Fianarantsoa Province harbor the intermediate hosts. The Mangoky River system and tributaries of the Tsiribihina present documented transmission sites. Swimming, wading, or any skin contact with untreated freshwater represents exposure risk. Chlorinated swimming pools and coastal Indian Ocean waters do not transmit the parasite. No pre-travel vaccine exists. Diagnosis requires specialized blood testing or stool examination weeks after exposure, as initial infection produces minimal symptoms.
Typhoid fever transmission continues at rates substantially exceeding most neighboring Indian Ocean islands. Salmonella typhi spreads through contaminated food and water, with inadequate sanitation infrastructure in Antananarivo and provincial cities creating persistent exposure pathways. The oral typhoid vaccine provides 50 to 80 percent protection lasting five years. The injectable Vi polysaccharide vaccine offers similar protection for two years. Neither vaccine approaches the efficacy of routine childhood immunizations. Food safety practices reduce risk more effectively than vaccination alone. Street food in Antananarivo's markets and provincial towns including Mahajanga and Toliara represents the highest-risk consumption category. Bottled water remains widely available in tourist-serving areas. Tap water throughout Madagascar requires treatment or avoidance. The disease manifests one to three weeks post-exposure with sustained fever, headache, and gastrointestinal symptoms. Antibiotic resistance has emerged in Malagasy isolates, complicating treatment protocols.
Rabies circulates in terrestrial mammal populations including dogs, cats, and endemic species like the ring-tailed lemur. Madagascar records sporadic human cases annually, with underreporting likely given limited surveillance capacity outside Antananarivo. The pre-exposure vaccination series consists of three doses administered over 21 to 28 days. This does not eliminate post-exposure treatment requirements but reduces the number of doses needed after potential exposure and eliminates the need for rabies immune globulin, which remains unavailable in most Malagasy medical facilities. Post-exposure prophylaxis requires administration within hours to days of exposure to prevent invariably fatal encephalitis. Antananarivo maintains limited vaccine stocks at Institut Pasteur de Madagascar and private clinics. Supplies outside the capital are unreliable. The disease risk differentiates Madagascar from destinations where canine rabies has been eliminated through vaccination programs.
Hepatitis A transmission occurs through contaminated food and water at rates typical for countries with developing sanitation infrastructure. The two-dose vaccine series provides protective immunity lasting at least 20 years in most recipients. Single-dose protection begins within two weeks, covering travelers who receive vaccination shortly before departure. Street food, raw produce washed in local water, and ice in beverages represent common exposure sources. Hepatitis E follows similar transmission patterns but lacks a widely available vaccine. Both viruses produce acute liver inflammation with jaundice, dark urine, and fatigue typically resolving over weeks to months. Chronic infection does not result from hepatitis A, distinguishing it from hepatitis B and C, which spread through blood and sexual contact rather than food and water.
Japanese encephalitis is not present in Madagascar despite the country's location within the Indian Ocean region. The virus remains confined to Asia and the Western Pacific. Yellow fever does not occur naturally in Madagascar, but the country enforces yellow fever vaccination certificate requirements for travelers arriving from endemic countries. The risk list includes most of sub-Saharan Africa and tropical South America. Travelers transiting through airports in these regions for more than 12 hours require proof of vaccination. Antananarivo's Ivato International Airport implements this screening. Aedes aegypti mosquitoes, which transmit yellow fever, dengue, chikungunya, and Zika, have established populations in Madagascar, meaning introduction of these viruses could lead to local transmission.
Dengue virus transmission has been documented in Madagascar since at least 2006, with periodic outbreaks in urban areas. Aedes aegypti and Aedes albopictus mosquitoes transmit the virus through daytime biting, distinguishing them from the nocturnal Anopheles species that spread malaria. No vaccine is available for travelers without previous dengue infection. The tetravalent Dengvaxia vaccine carries risks of severe disease enhancement in dengue-naive recipients. Antananarivo, Toamasina, and coastal cities experience sporadic transmission. The disease manifests with sudden high fever, severe headache, pain behind the eyes, joint and muscle pain, and rash. Most infections resolve within a week. Severe dengue progresses to hemorrhagic fever or shock syndrome in a small percentage of cases, typically during second infections with a different viral serotype.
Chikungunya emerged in Madagascar during a 2006 outbreak that affected approximately 170,000 people, primarily in coastal regions. The same Aedes mosquitoes transmit this alphavirus. Symptoms include sudden fever and severe joint pain that may persist for months. No vaccine exists for travelers. Outbreaks occur sporadically rather than continuously. Zika virus has been detected in Madagascar, though large outbreaks have not been documented as of available surveillance data. Pregnant women face fetal development risks from Zika infection. The CDC recommends discussing Madagascar travel with healthcare providers during pregnancy.
Tuberculosis incidence in Madagascar was estimated at 233 cases per 100,000 population in 2020 according to WHO data. This places Madagascar in the high-burden category. Transmission occurs through respiratory droplets during prolonged indoor contact. Short-term travelers face minimal risk unless working in healthcare settings or maintaining extended close contact with local populations. The BCG vaccine provides variable protection, primarily reducing severe childhood disease rather than preventing adult pulmonary tuberculosis. Drug-resistant strains comprise approximately 3 percent of new cases based on 2019 surveillance.